Healthcare / BiotechnologyTaiwan
$30.35
+0.25 (+0.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $205.4M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
18.7x
↓EV/EBITDA
10.3x
↓ROE
8.7%
↑Gross Margin
27.7%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.7%
FCF CAGR
—
FCF margin
7.2%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.94B · net income $162.9M · FCF $140.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.94B | $1.94B | $1.85B | $1.68B | $2.24B |
| Net Income | $162.9M | $162.9M | $128.0M | $115.8M | $181.8M |
| EBITDA | $254.2M | $254.2M | $221.6M | $221.1M | $299.1M |
| EPS | — | — | 1.27 | 1.15 | 1.81 |
| Gross Margin | 27.7% | 27.7% | 28.1% | 31.7% | 25.7% |
| Operating Margin | 8.0% | 8.0% | 6.9% | 8.6% | 7.9% |
| Net Margin | 8.4% | 8.4% | 6.9% | 6.9% | 8.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.09 | 0.10 | 0.13 |
| Current Ratio | 3.14 | 3.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $140.9M | $140.9M | $303.4M | $205.4M | $-13.6M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 7.0% | 6.4% | 10.0% |
| Valuation | |||||
| P/E | 18.73 | 18.73 | 23.50 | 32.22 | 14.01 |
| EV/EBITDA | 10.29 | 10.29 | 11.87 | 15.90 | 8.24 |
| P/B | 1.62 | 1.62 | 1.64 | 2.07 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | 5.0% | 5.0% | 10.5% | -25.3% | — |
| EPS Growth | — | — | 10.4% | -36.5% | — |
| Dividend Yield | 4.3% | 4.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.27 → n/d
Residual
-3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.